AtaGenix Laboratories
AtaGenix's Antibody Discovery Platform provides end-to-end custom antibody development from antigen to validated monoclonal antibody. With 3 core discovery engines (phage display, hybridoma, single B cell), 9+ specialized service types, and integrated downstream engineering (humanization, affinity maturation, bispecific design), we cover the full spectrum of antibody development needs for research, diagnostics, and therapeutic programs.
3
Core Discovery Engines
95.4%
Hybridoma Success Rate
10¹¹
Phage Library Diversity
400+
Publications Citing AtaGenix
Not sure which platform is right for your project? Use this table to match your requirements to the best discovery route.
| Service | Best For | Species | Timeline |
| Rabbit Single B Cell | Highest affinity (10–100x vs mouse); PTMs, small molecules, easy humanization | Rabbit | 16–20 wks |
| Rapid Hybridoma | Traditional mouse mAb with hybridoma cell line; 95.4% success rate; broad application validation | Mouse | 4–6 months |
| Phage Display | Fully human Abs without immunization; 10¹¹ library diversity; scFv/Fab/VHH formats | Human, camelid, multi-species | 2–14 wks |
| Naïve Library Panning | 9 pre-built libraries (human, VHH, rabbit, dog, cat); fastest path; no immunization | Multi-species | 2–3 wks (hits) |
| Immune Library Construction | Custom library from immunized donors; high target-specific affinity; any species | Rabbit, mouse, alpaca, llama, sheep | 7–10 wks (build) |
| Polyclonal Antibody | Multi-epitope recognition; fast turnaround; rabbit, mouse, rat, guinea pig, sheep, chicken (IgY) | 6 species | 6–8 wks |
| Bispecific Antibody | KIH, CrossMab, BiTE, tandem scFv, bi-Nanobody; dual-target engagement | N/A (from sequences) | ~5 wks |
| Peptide Synthesis | Custom immunogen prep; up to 101 aa; phospho/methyl/acetyl modifications; KLH/BSA conjugation | N/A | ~2 wks |
If your project has a specific functional requirement, these specialized services add targeted screening beyond standard binding ELISA.
| Service | Description | Key Differentiator |
| Anti-Small Molecule | Hapten modification, carrier conjugation, antibody production for food safety, drug screening, biomarkers | Free antigen assessment; hapten-specific affinity purification; 30+ drugs covered in abinScience catalog |
| Anti-PTM | Phospho, methyl, acetyl, glyco, succinyl, lactyl — modification-specific antibodies with two-round purification | Free antigen design; modified + unmodified peptide pair; guaranteed specificity for modified form only |
| Anti-Idiotype | Neutralizing, non-neutralizing, drug-target complex Anti-ID Abs for PK/ADA/NAb assays | Guaranteed sandwich ELISA pairs; 120+ catalog Anti-ID products on abinScience; 196 PK ELISA kits |
| Neutralizing / Blocking | Antibodies with confirmed functional activity: virus neutralization, receptor blocking, toxin inhibition | Functional screening (competitive ELISA, cell-based neutralization) + IC50 potency characterization included |
I need the fastest antibody possible
→ Naïve Library Panning — hits in 2–3 weeks from 9 pre-built libraries (human, VHH, rabbit, dog, cat), no immunization needed.
I need a fully human therapeutic antibody
→ Phage Display with LiAb-SFMAX™ human library (7.38 × 10¹⁰ diversity). No humanization step needed.
I need highest-affinity rabbit mAb
→ Rabbit Single B Cell (Xten™ Mab) — 10–100x higher affinity than mouse, ideal for PTMs and difficult antigens.
I need a traditional mouse mAb with cell line
→ Rapid Hybridoma — 95.4% success rate, hybridoma cell line delivered, IHC/IF/FC application-grade screening available.
I need PK/ADA bioanalytical reagents
→ Anti-Idiotype + abinScience catalog — 120+ Anti-ID products, 196 PK ELISA kits, 28 NAb kits off the shelf.
I need a VHH nanobody
→ Naïve VHH Library (LiAb-VHHMAX™, 2.71 × 10¹⁰) for speed, or Immune Library from immunized camelids for highest affinity.
Explore real-world yeast protein expression case studies from AtaGenix. Our Pichia pastoris and Saccharomyces cerevisiae platforms deliver high-yield recombinant proteins with proper folding and glycosylation — supporting enzyme production, diagnostic antigen development, and antibody screening applications.
A 2021 Small Methods study used dual phage display libraries — an overlapping spike peptide library for epitope mapping and a 8.7×10⁹ patient-derived ScFv library for antibody discovery — to identify three immunodominant RBM epitopes (S431–454, S470–486, S501–515) and isolate human neutralizing monoclonal antibodies from COVID-19 patients. S470–486 emerged as the key protective epitope (diagnostic AUC ~1.0; mouse immunization produced neutralizing antibodies). AtaGenix provided phage library construction, biopanning screening, and antibody expression services that enabled the 10⁹-scale discovery campaign. DOI: 10.1002/smtd.202100058.